Loading stock data…
Lisata Therapeutics (LSTA)
$1.86+0.20 (+12.05%)
Market ClosedLast close Sep 8
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lisata Therapeutics, Inc. in the Healthcare sector is trading at $1.86 with a market capitalization of $31M. The stock is currently 63% below its 52-week high of $5.07, remaining 40.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 74 is overbought against a weak tape. The Whystock Score of 0/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 74 against a weak tape — risk of pullback
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $100,000 | $0↓ | $70,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.99M↑ | -$4.94M↓ | -$3.08M↑ | -$4.41M↑ | -$4.87M |
| Net Income | -$2.93M↑ | -$4.49M↓ | -$2.95M↑ | -$4.25M↑ | -$4.66M |
Peer Comparison
JNJUNHPFE
Fundamentals
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.42M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.65%
Volume
Today's trading volume
252,476
Recent News
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial...
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones. Kuva's wholly owned subsidiary Kuva Acquisition Corp...
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will...
Lisata Therapeutics And 2 Other Penny Stocks Worth Watching
Major stock indexes in the United States recently rebounded, closing sharply higher after a period of volatility driven by geopolitical tensions and economic policy shifts. In this context, investors are increasingly looking for opportunities that balance affordability with growth potential. While the term 'penny stocks' may seem outdated, it still refers to smaller or emerging companies that can offer significant value when backed by strong financials. In this article, we explore three penny...